ScholarLens Back to search
2012•Journal of psychiatryRequires access

A control study between paroxetine monotherapy and paroxetine combined with risperidone for the treatment of refractory depression with psychotic symptoms

Xiaoling Liu

Open publisher page 0 citations

Abstract

Objective To evaluate the efficacy and safety of paroxetine combined with risperidone in the treatment of refractory depression with psychotic symptoms.Methods 100 patients were randomized into study group(50 cases) treated with paroxetine combined with risperidone and control group(50 cases) treated with paroxetine monotherapy for 12 weeks.Hamilton Depression Scale(HAMD) and Treatment Emergent Symptom Scale(TESS) were used to assess the efficacy and side effects respectively at the baseline and at the 2nd,4th,6th,12th weekend of the treatment.Results Efficacy of study group was significantly better than that in control group.The prevalence of extrapyramidal side effect(EPS) and weight gain in study group were higher than those in control group.Conclusion Risperidone can play a synergistic action in the treatment of refractory depression with psychotic symptoms.

About this research paper

What this paper is about

Objective To evaluate the efficacy and safety of paroxetine combined with risperidone in the treatment of refractory depression with psychotic symptoms.Methods 100 patients were randomized into study group(50 cases) treated with paroxetine combined with risperidone and control group(50 cases) treated with paroxetine monotherapy for 12 weeks.Hamilton Depression Scale(HAMD) and Treatment Emergent Symptom Scale(TESS) were used to assess the efficacy and side effects respectively at the baseline and at the 2nd,4th,6th,12th weekend of the treatment.Results Efficacy of study group was significantly better than that in control group.The prevalence of extrapyramidal side effect(EPS) and weight gain in study group were higher than those in control group.Conclusion Risperidone can play a synergistic action in the treatment of refractory depression with psychotic symptoms.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To evaluate the efficacy and safety of paroxetine combined with risperidone in the treatment of refractory depression with psychotic symptoms.Methods 100 patients were randomized into study group(50 cases) treated with paroxetine combined with risperidone and control group(50 cases) treated with paroxetine monotherapy for 12 weeks.Hamilton Depression Scale(HAMD) and Treatment Emergent Symptom Scale(TESS) were used to assess the efficacy and side effects respectively at the baseline and at the 2nd,4th,6th,12th weekend of the treatment.Results Efficacy of study group was significantly better than that in control group.The prevalence of extrapyramidal side effect(EPS) and weight gain in study group were higher than those in control group.Conclusion Risperidone can play a synergistic action in the treatment of refractory depression with psychotic symptoms.

Key concepts: Paroxetine, Risperidone, Hamd, Depression (economics), Refractory (planetary science), Extrapyramidal symptoms, Medicine, Clinical efficacy

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
A control study between paroxetine monotherapy and paroxetine combined with risperidone for the treatment of refractory depression with psychotic symptoms — Research Paper | ScholarLens